Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
US Department of Justice
AstraZeneca
Accenture
UBS

Generated: August 25, 2019

DrugPatentWatch Database Preview

Ibritumomab tiuxetan - Biologic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for ibritumomab tiuxetan

US Patents for ibritumomab tiuxetan

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2033-03-11 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial YALE UNIVERSITY (New Haven, CT) 2032-05-02 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial NOXXON Pharma AG (Berlin, DE) 2030-09-09 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial YALE UNIVERSITY (New Haven, CT) 2038-11-11 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial GENOSCIENCE PHARMA (Marseilles, FR) 2039-01-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ibritumomab tiuxetan

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004000036 Germany   Try a Free Trial FORMER OWNER: BIOGEN IDEC INC.(N.D.GES.D.STAATES DELAWARE), SAN DIEGO, CALIF., US
780 Luxembourg   Try a Free Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
C0018 France   Try a Free Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
089 Luxembourg   Try a Free Trial 91089, EXPIRES: 20181112
620 Luxembourg   Try a Free Trial 91620, EXPIRES: 20181112
0822 Netherlands   Try a Free Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Citi
QuintilesIMS
Julphar
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.